FDA Updates OTC Alli (Orlistat) Label for Rare Kidney Injury Warning

The FDA approved updated labeling for the OTC weight-loss medicine alli (orlistat) 60 mg to more clearly warn about a rare but potentially serious kidney risk. The label changes—approved June 10, 2026—add extra guidance for people who have had kidney disease or kidney stones.

If you or a family member is considering or already using alli, the most important practical step is to know the warning symptoms and understand when to get help.

What’s different in the OTC alli label now?

In its Drug Safety Communication, the FDA says it approved changes to the Drug Facts label for OTC alli (orlistat) 60 mg. The updates are intended to make the kidney risk information easier to find and act on.

Who should be extra cautious?

The updated labeling advises consumers to ask a health care provider before using alli if they have ever had kidney disease or kidney stones.

FDA symptom checklist: stop and get medical guidance

The FDA says consumers should stop using alli and ask a doctor if they develop symptoms that could indicate kidney injury or kidney stones. The label lists warning signs such as:

Back or groin pain
Painful urination
Blood in the urine
Feet and leg swelling
Less frequent urination

These symptoms can have many causes, and the FDA’s goal is to help people recognize when kidney-related evaluation is warranted.

How common is this risk?

FDA characterizes acute kidney injury in this setting as a rare side effect. In its review, FDA identified 12 cases of kidney complications associated with alli use (from postmarketing safety reports and published literature). FDA also notes that the true number of cases could be higher because side effects are not always reported and some reports lacked complete clinical details.

The FDA further cautions that people in some reports had other possible contributors to kidney problems. In other words, the label update reflects real-world safety signals and biological plausibility rather than results from a single randomized trial.

What readers can do right now

Check the Drugs Facts label, especially the section about when to ask a clinician.
Ask about fit and alternatives if you (or the person you care for) has a history of kidney disease or kidney stones.
Use the symptom checklist as a “when to call” guide: if symptoms occur, follow the FDA-labeled instruction to stop the product and seek medical guidance promptly.
Report possible side effects if they occur, so regulators can track emerging safety information over time (FDA points consumers to report via MedWatch).

How this fits into broader weight-loss planning

Weight-loss approaches are often healthiest when they’re personalized and supported by evidence-based lifestyle changes. The CDC emphasizes that good nutrition, physical activity, stress management, and sleep support healthy weight management—and that you should talk with a health care provider if you have questions about medication choices.

Professional guidance also matters for medication selection. Clinical guidance frameworks for obesity care include pharmacologic options, and AGA’s clinical guidance discusses how clinician counseling helps determine which options may be appropriate for a given patient.

So the FDA warning is about safe use and awareness, while guideline-based counseling helps frame where (or whether) orlistat fits into an overall care plan.

Conversation starters for clinicians, caregivers, and patients

“Does my history of kidney disease or kidney stones mean I should avoid OTC or prescription orlistat?”
“If I develop back/groin pain, painful urination, blood in my urine, swelling, or less frequent urination, what should I do next?”
“Are there other evidence-based weight-loss options that better match my medical history?”
“How should we monitor kidney health if we decide on any weight-loss medication?”

Bottom line

The FDA’s June 10, 2026 label update for OTC alli (orlistat) 60 mg increases clarity around a rare kidney-related risk. If you have ever had kidney disease or kidney stones, the label says to ask a health care provider before using alli—and if kidney injury or kidney-stone symptoms appear, the FDA advises stopping the product and seeking medical guidance promptly.

Key sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.